Dov Pharmaceuticals fka DOVP

[Virgilio]

There's not a correct story, there's a company out there that has a very strong pipeline. It's a company that wanted to settle things straight out before concluding any kind of partnership, as this was mandatory in order to assess all risks.

This is a company that started a series of initiatives in order to raise cash, and that now could seek partners for:

1) Dov 21,947;
2) Dov 102,677;
3) Dov 216,303;
4) Dov Diltiazem;
5) Bicifadine.

If Dovp would have had the time in order to settle things well, they could have raised at least 125M in upfront payments for these drugs, problem is that they are time constrain as there are only 6 business days left before they have to declare BK. Hopefully they might be able to partner Dov 21,947 or to sell Dov 216,303 back to Merck with a revisited deal.

All we have to do is to wait and see, I don't think debenture holders would like this stock into BK as in the biotech world time is cash so they need to avoid Ch.11. Time will tell.